Mutual of America Capital Management LLC Acquires New Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Mutual of America Capital Management LLC acquired a new stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) during the fourth quarter, HoldingsChannel reports. The fund acquired 64,214 shares of the company’s stock, valued at approximately $2,344,000.

A number of other large investors also recently modified their holdings of SWTX. State Street Corp raised its holdings in shares of SpringWorks Therapeutics by 143.7% during the 2nd quarter. State Street Corp now owns 3,889,249 shares of the company’s stock valued at $95,753,000 after buying an additional 2,293,359 shares in the last quarter. BlackRock Inc. raised its holdings in shares of SpringWorks Therapeutics by 31.3% during the 2nd quarter. BlackRock Inc. now owns 4,259,391 shares of the company’s stock valued at $111,681,000 after buying an additional 1,015,359 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of SpringWorks Therapeutics by 191.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 795,463 shares of the company’s stock valued at $20,475,000 after buying an additional 522,571 shares in the last quarter. Point72 Asset Management L.P. increased its stake in SpringWorks Therapeutics by 121,682.7% in the 2nd quarter. Point72 Asset Management L.P. now owns 463,992 shares of the company’s stock worth $12,166,000 after purchasing an additional 463,611 shares during the period. Finally, Vanguard Group Inc. lifted its position in SpringWorks Therapeutics by 16.5% in the third quarter. Vanguard Group Inc. now owns 3,196,045 shares of the company’s stock valued at $91,184,000 after purchasing an additional 451,928 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SWTX shares. Guggenheim started coverage on SpringWorks Therapeutics in a research report on Monday, February 5th. They issued a “buy” rating and a $75.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on SpringWorks Therapeutics from $73.00 to $74.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Wedbush boosted their price objective on SpringWorks Therapeutics from $60.00 to $70.00 and gave the company an “outperform” rating in a research report on Monday, February 26th. HC Wainwright boosted their price objective on SpringWorks Therapeutics from $73.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Finally, Barclays boosted their price objective on SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, SpringWorks Therapeutics presently has an average rating of “Buy” and an average price target of $68.00.

Insider Buying and Selling

In related news, insider Daniel Pichl sold 15,000 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $50.10, for a total value of $751,500.00. Following the sale, the insider now directly owns 45,212 shares of the company’s stock, valued at $2,265,121.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.61% of the stock is owned by insiders.

SpringWorks Therapeutics Price Performance

SWTX opened at $40.10 on Friday. SpringWorks Therapeutics, Inc. has a 52-week low of $18.00 and a 52-week high of $53.92. The stock’s 50 day moving average price is $47.96 and its 200-day moving average price is $37.07.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its earnings results on Tuesday, February 27th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.24) by ($0.20). The firm had revenue of $5.45 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same quarter in the previous year, the business earned ($1.19) earnings per share. As a group, sell-side analysts predict that SpringWorks Therapeutics, Inc. will post -4.71 earnings per share for the current fiscal year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.